HK1203055A1 - Treatment for multiple sclerosis - Google Patents

Treatment for multiple sclerosis

Info

Publication number
HK1203055A1
HK1203055A1 HK15103598.3A HK15103598A HK1203055A1 HK 1203055 A1 HK1203055 A1 HK 1203055A1 HK 15103598 A HK15103598 A HK 15103598A HK 1203055 A1 HK1203055 A1 HK 1203055A1
Authority
HK
Hong Kong
Prior art keywords
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
HK15103598.3A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Panzara
Alfred Sandrock
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HK1203055A1 publication Critical patent/HK1203055A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15103598.3A 2004-11-19 2015-04-13 Treatment for multiple sclerosis HK1203055A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62970004P 2004-11-19 2004-11-19

Publications (1)

Publication Number Publication Date
HK1203055A1 true HK1203055A1 (en) 2015-10-16

Family

ID=36407818

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103598.3A HK1203055A1 (en) 2004-11-19 2015-04-13 Treatment for multiple sclerosis

Country Status (8)

Country Link
US (1) US20090202527A1 (xx)
EP (2) EP2808033A1 (xx)
JP (4) JP2008520717A (xx)
CN (2) CN103169965A (xx)
AU (1) AU2005306399B2 (xx)
CA (1) CA2587597A1 (xx)
HK (1) HK1203055A1 (xx)
WO (1) WO2006055871A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
AU2004269903B2 (en) 2003-09-09 2010-09-02 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
NZ556105A (en) * 2004-12-03 2009-12-24 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis
ES2916649T3 (es) 2007-02-08 2022-09-21 Biogen Ma Inc Composiciones y usos para el tratamiento de la esclerosis múltiple
MX2009013593A (es) * 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
AU2011239512B2 (en) 2010-04-16 2016-01-21 Biogen Ma Inc. Anti-VLA-4 antibodies
CA2916028A1 (en) * 2013-07-05 2015-01-08 Biogen Ma Inc. Compositions and methods for treatment of stroke
CA2979397A1 (en) 2015-03-12 2016-09-15 Board Of Trustees Of Michigan State University Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
WO2017134305A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Bispecific signaling agents and uses thereof
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
JP2020505955A (ja) 2017-02-06 2020-02-27 オリオンズ バイオサイエンス インコーポレイテッド 標的化改変型インターフェロン及びその使用
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
MA49645A (fr) 2017-07-20 2021-03-31 Univ Virginia Patent Foundation Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire
US20220119532A1 (en) * 2019-01-14 2022-04-21 University Of Virginia Patent Foundation Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2148712C (en) * 1992-11-13 2012-01-17 Thalia Papayannopoulou Peripheralization of hematopoietic stem cells
DE69419721T2 (de) * 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6432404B1 (en) * 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
KR100367948B1 (ko) * 1994-01-25 2003-07-12 엘란 파마슈티칼스, 인크. 백혈구부착분자vla-4에대한인체화된항체
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
AU2203199A (en) * 1997-12-30 1999-07-19 Bioabsorbable Concepts, Inc. Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
AU767066B2 (en) * 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
AU2446801A (en) * 1999-12-23 2001-07-03 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
WO2001055112A1 (en) 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
AU4589901A (en) * 2000-03-31 2001-10-15 Scripps Research Inst Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
CN1541105A (zh) * 2001-06-11 2004-10-27 转新疗法公司 用维生素b12和干扰素联合治疗病毒性、增殖性和炎性疾病的方法
WO2003053220A2 (en) * 2001-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040203031A1 (en) * 2002-04-03 2004-10-14 University Of Pennsylvania Methods for determining drug responsiveness
WO2003070171A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
AU2003213231A1 (en) * 2002-02-25 2003-09-09 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
AU2003284246A1 (en) * 2002-10-16 2004-05-04 Samuel F. Hunter Method for treatment of demyelinating central nervous system disease using gm-csf
US7576101B2 (en) * 2003-01-24 2009-08-18 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
MY162623A (en) * 2003-02-10 2017-06-30 Biogen Ma Inc Immunoglobulin formulation and method of preparation thereof
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
JP2007532681A (ja) * 2004-04-16 2007-11-15 ジェネンテック・インコーポレーテッド Ｂ細胞の枯渇を増大させる方法
PT2322556E (pt) * 2004-09-03 2016-02-15 Genentech Inc Antagonistas humanizados anti-beta7 e suas utilizações
JP2008542407A (ja) * 2005-06-09 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２，６キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用
AU2006268227A1 (en) * 2005-07-08 2007-01-18 Xencor, Inc Optimized anti-Ep-CAM antibodies
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists

Also Published As

Publication number Publication date
EP1827491A2 (en) 2007-09-05
CN103169965A (zh) 2013-06-26
JP2012233009A (ja) 2012-11-29
JP2009091360A (ja) 2009-04-30
EP2808033A1 (en) 2014-12-03
US20090202527A1 (en) 2009-08-13
JP2015044873A (ja) 2015-03-12
WO2006055871A3 (en) 2006-08-03
AU2005306399A1 (en) 2006-05-26
JP2008520717A (ja) 2008-06-19
CA2587597A1 (en) 2006-05-26
AU2005306399B2 (en) 2012-02-09
WO2006055871A2 (en) 2006-05-26
EP1827491A4 (en) 2010-07-14
CN101102792A (zh) 2008-01-09

Similar Documents

Publication Publication Date Title
HK1203055A1 (en) Treatment for multiple sclerosis
IL179139A0 (en) Method for treating multiple sclerosis
EP1789086A4 (en) PROLONGED TREATMENT OF MULTIPLE SCLEROSIS
GB0423554D0 (en) Therapeutic compounds
ZA200609542B (en) Therapeutic compounds
GB0428318D0 (en) Treatment for severe melancholic depression
IL197818A0 (en) Multiple sclerosis therapy
GB2430002B (en) Well treatment
GB0420424D0 (en) Therapeutic compounds
EP1809276A4 (en) PROCESSING PROCESS
IL180487A0 (en) Medicament
GB0426141D0 (en) Treatment
GB0424085D0 (en) Well treatment
HU0400305D0 (en) Set for spine-fixture
GB0407354D0 (en) Treatment apparatus
GB0427138D0 (en) Therapeutic compounds
GB0417560D0 (en) Therapeutic compounds
GB0423767D0 (en) Therapeutic compounds
GB0426942D0 (en) Medicament
GB0409098D0 (en) Medicament
AU2005900974A0 (en) Treatment for multiple sclerosis
GB0412411D0 (en) Treatment
GB0614058D0 (en) Treatment for multiple sclerosis
ZA200704868B (en) Cladrlbine regimen for treating multiple sclerosis
GB0413584D0 (en) Well treatment